Rapport Therapeutics, Inc. (RAPP)

NASDAQ: RAPP · USD

$22.5

-5.05 (-18.3%)· Recorded snapshot

Market cap	1.1B
Revenue (ttm)	20M
Net income (ttm)	-137.2M
EPS (ttm)	-$3.05
Shares out	48M
Volume	5,606,655
Beta	1.22

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 20M
Net income (ttm): -137.2M
EPS (ttm): -$3.05
Market cap: 1.1B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-40

P25 -113.8P50 -46.5P75 -0.9

ROIC-27.1

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All RAPP indicators

Market & fundamental data

Available fields

181

Groups with data

Currency

USD

Showing 181 of 181 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0002012593
Company name	Rapport Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	75383L102
Earnings date	2026-11-09
Earnings time	bmo
Employees	84
Enterprise value	$653.1M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2022
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2024-06-07
Is primary listing	Yes
Is SPAC	No
ISIN number	US75383L1026
Last 10-K release date	2026-03-10
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.1B
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$22.49
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	RAPP
U.S. state	Massachusetts
Website	https://www.rapportrx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-13.57%
EV/Sales	33.13x
FCF / EV yield	-14.66%
FCF yield	-8.92%
Forward EV/Sales	9,939.33x
Forward P/S	16,328.59x
P/B ratio	3.12x
P/S ratio	54.43x
Price / tangible book value	2.57x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	-109.39%
Operating margin	-767.58%
Pretax margin	-685.8%
Profit per employee	$-1.6M
Revenue per employee	$238,095
ROA	-25.78%
ROCE	-35.66%
ROE	-39.96%
ROIC	-27.09%
SBC / revenue	122.96%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	2
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-467,000
Depreciation and amortization	$960,000
EBIT	$-153.5M
EBITDA	$-152.6M
EPS	$-3.05
FCF per share	$-2.02
Financing cash flow	$272.8M
Free cash flow	$-97.1M
Free cash flow minus SBC	$-121.7M
Gross profit	$-21.9M
Investing cash flow	$-167.6M
Net cash flow	$8.5M
Net income	$-137.2M
Operating cash flow minus SBC	$-121.3M
Operating income	$-153.5M
Revenue	$20M
Stock-based compensation	$24.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	20.27
Book value per share	$8.82
Debt / equity	0.02
Long-term assets	$12.1M
Long-term liabilities	$7.6M
Net cash (debt)	$426M
Net cash / market cap	39.13%
Net cash growth	71.36%
Net debt / equity	-1.01
Piotroski F-Score	1
Property, plant and equipment	$11.1M
Shareholders' equity	$422.9M
Tangible book value	$422.9M
Tangible book value per share	$8.82
Total assets	$459M
Total cash	$436.1M
Total debt	$10.1M
Total liabilities	$36.1M
WACC	10.86%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.05
Current assets	$446.9M
Current liabilities	$28.4M
Current ratio	15.72
Net working capital	$-15.2M
Quick ratio	15.35
Working capital	$418.4M
Working capital turnover	0.06

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-27.52%
Dividend yield	0%
Shareholder yield	-27.52%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$38.22
1D price change	-18.34%
1M price change	-34.27%
1M total return	-34.27%
1W price change	-24.11%
1W total return	-24.11%
1Y price change	-15.82%
1Y return CAGR	-15.83%
1Y total return	-15.82%
20-day SMA	$28.75
200-day SMA	$35.67
3M price change	-47.09%
3M total return	-47.09%
50-day SMA	$37.65
50-day SMA vs 200-day SMA	50over200
52-week high	$52.93
52-week high date	2026-08-27
52-week low	$22.10
52-week low date	2026-10-28
6M price change	-37.03%
6M total return	-37.03%
All-time high	$52.93
All-time high date	2026-08-27
All-time low	$6.43
All-time low date	2025-03-04
Average true range (ATR)	$2.71
Average volume	1.1M
Beta (1Y)	2.01
Beta (2Y)	1.68
Beta (5Y)	1.22
Change from 52-week high	-57.51%
Change from 52-week low	1.79%
Change from all-time high	-57.89%
Change from all-time low	246.66%
Change from open	-0.04%
Day's gap	-18.3%
Dollar volume	$126.1M
High price	$23.83
Low price	$22.10
Monthly RSI	44.39
Open price	$22.50
Position in 52-week range	22.54%
Premarket change	-18.3%
Premarket close	$27.54
Premarket price	$22.50
Premarket volume	373.2K
Previous close	$27.54
Price vs 150-day SMA	-41.67%
Price vs 20-day SMA	-22.46%
Price vs 200-day SMA	-37.52%
Price vs 50-day SMA	-40.8%
Relative volume	4.89
Return from IPO open	26.06%
Return from IPO price	33.47%
RSI	28.93
Sharpe ratio	-0.02
Sortino ratio	0.06
Volume	5.6M
Weekly RSI	28.95
YTD price change	-26.53%
YTD total return	-26.53%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	32.3M
Float percentage	67.4%
Shares change (QoQ)	0.5%
Shares change (YoY)	27.52%
Shares held by insiders	4.18%
Shares held by institutions	79.52%
Shares outstanding	48M
Short % of float	9.44%
Short % of shares	6.36%
Short ratio	6.7 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	158

Deeper analysis on RAPP

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this RAPP report

Is a complete RAPP research report available?

No complete published report is available for Rapport Therapeutics, Inc. (RAPP) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Rapport Therapeutics, Inc. (RAPP)

Price

Financial snapshot

Fair-value bridge

Latest news · RAPP

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All RAPP indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on RAPP

Frequently asked questions